The pharmaceutical company Hemofarm announced today that it will invest 40 million euros in plants, new equipment and the application of the latest standards.
Hemofarm has been operating for 61 years and is a leader in the pharmaceutical market and one of the largest exporters in Serbia.
Since 2006, Hemofarm has been part of the Stad Group, one of the leading pharmaceutical companies in Europe, which has invested around 300 million euros in the modernization of its plants, equipment and new plants.
This year’s business plan envisages investments in Hemofarm’s operations in Serbia (plants in Vrsac and Sabac) of around 28 million euros, in Bosnia and Herzegovina (Hemofarm Banja Luka) almost 10 million euros, while further improvement of the company’s operations in Montenegro (Hemomont in Podgorica) 1.5 million euros will be invested.
Investments are also planned for the purchase of new laboratory equipment in Timisoara, which operates within the Hemofarm Group, and serves for the certification of drugs exported to EU countries.
“Hemofarm is big because it produces drugs for the whole world, and it has grown and developed thanks to regular investments, constant innovations in production and continuous investment in people and processes. The fact that we are part of a single Stad that strongly stands in the field of innovation in all segments of pharmaceutical development, is the reason for our success. We return it with a leading position in the market, record production in accordance with the principles of sustainable development and the maximum amount of quality drugs available in pharmacies on three continents,” said Hemofarm CEO Roland Zeliger.
He added that during the pandemic, Hemofarm showed what it means to take care of people’s health through 24-hour production and regular supply to the market.
On the company’s birthday, Hemofarm employees voluntarily donated blood in a transfusion bus that was placed in front of the entrance to the Vrsac factory, Beta reports.
